Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic Biomarker.
IL-8
advanced CRC
anti-angiogenic drugs
chemotherapy
prognosis
tumor–stroma interactions
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
19 Oct 2022
19 Oct 2022
Historique:
received:
15
09
2022
revised:
09
10
2022
accepted:
16
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Among soluble actors that have emerged as druggable factors, the chemokine interleukin-8 (IL-8) has emerged as a possible determinant of response to immunotherapy and targeted treatment in several cancer types; however, its prognostic/predictive role in colorectal cancer (CRC) remains to be established. We: (i) conducted a systematic review of published literature on IL-8 expression in CRC; (ii) searched public transcriptomics databases; (iii) investigated IL-8 expression, by tumor and infiltrating cells, in a series of CRC samples; and (iv) carried out a meta-analysis of published literature correlating IL-8 expression and CRC prognosis. IL-8 possesses an important role as a mediator of the bidirectional crosstalk between tumor/stromal cells. Transcriptomic analysis indicated that specific IL-8 transcripts were significantly overexpressed in CRC compared to normal colon mucosa. Moreover, in our series we observed a statistically significant correlation between PTEN-loss and IL-8 expression by infiltrating mononuclear and tumor cells. In total, 12 papers met our meta-analysis inclusion criteria, demonstrating that high IL-8 levels significantly correlated with shorter overall survival and progression-free survival. Sensitivity analysis demonstrated a highly significant correlation with outcome for circulating, but not for tissue-detected, IL-8. IL-8 is overexpressed in CRC tissues and differentially produced by tumor or stromal components depending on CRC genetic background. Moreover, circulating IL-8 represents a strong prognostic factor in CRC, suggesting its use in the refining of prognostic CRC assessment and potentially the tailoring of therapeutic strategies in individual CRC patients.
Identifiants
pubmed: 36289899
pii: biomedicines10102631
doi: 10.3390/biomedicines10102631
pmc: PMC9599846
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bando Interno Ricerca Corrente IRE 2021
ID : n.a.
Organisme : Italian Association for Cancer Research
ID : AIRC IG 20583
Organisme : Ministry of Education, Universities and Research
ID : B39J21037270006
Organisme : Ministero della Salute
ID : FIMPCUP_J38D19000690001
Organisme : Italian Association for Cancer Research
ID : n.a.
Références
Cells. 2022 Jun 09;11(12):
pubmed: 35741003
Br J Cancer. 2020 Aug;123(4):610-618
pubmed: 32488137
BMC Cancer. 2014 Jul 28;14:542
pubmed: 25069793
Theranostics. 2017 Apr 7;7(6):1543-1588
pubmed: 28529637
Int J Mol Sci. 2020 Dec 24;22(1):
pubmed: 33374459
J Leukoc Biol. 2002 Nov;72(5):847-55
pubmed: 12429706
J Oncol. 2019 May 5;2019:5373580
pubmed: 31191652
Cell Commun Signal. 2020 Mar 30;18(1):52
pubmed: 32228650
Acta Clin Belg. 2021 Apr;76(2):113-118
pubmed: 31610752
Science. 2015 May 8;348(6235):648-60
pubmed: 25954001
Br J Cancer. 2019 Feb;120(3):340-345
pubmed: 30636774
Cancer Manag Res. 2018 Nov 14;10:5659-5666
pubmed: 30532588
Cancer Chemother Pharmacol. 2018 Jun;81(6):1111-1119
pubmed: 29693201
Cancer Drug Resist. 2019 Dec 19;2(4):968-979
pubmed: 35582268
Front Immunol. 2022 Mar 17;13:795972
pubmed: 35371084
Br J Cancer. 2011 Feb 1;104(3):480-7
pubmed: 21285972
Int J Cancer. 2015 Feb 1;136(3):584-92
pubmed: 24916890
PLoS One. 2015 Apr 09;10(4):e0123484
pubmed: 25856316
Nat Med. 2020 May;26(5):693-698
pubmed: 32405063
Cytokine. 2020 Nov;135:155205
pubmed: 32721849
Clin Cancer Res. 2019 May 1;25(9):2887-2899
pubmed: 30705034
BMC Cancer. 2014 May 10;14:330
pubmed: 24885636
Int J Colorectal Dis. 2021 Jan;36(1):131-139
pubmed: 32920703
Cancer Med. 2013 Apr;2(2):234-42
pubmed: 23634291
Br J Cancer. 2013 Nov 26;109(11):2765-73
pubmed: 24149180
J Immunol. 2003 Mar 15;170(6):3369-76
pubmed: 12626597
Neoplasia. 2009 Aug;11(8):720-31
pubmed: 19649202
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Cancer Lett. 2015 May 28;361(1):22-32
pubmed: 25687885
Biochem Biophys Res Commun. 2011 Nov 18;415(2):245-51
pubmed: 22037460
Int J Mol Sci. 2016 Apr 28;17(5):
pubmed: 27136535
J Immunother Cancer. 2019 Sep 5;7(1):240
pubmed: 31488216
Int J Oncol. 2020 Jun;56(6):1551-1564
pubmed: 32236629
Clin Cancer Res. 2020 Sep 1;26(17):4661-4669
pubmed: 32532788
Commun Biol. 2020 Oct 1;3(1):546
pubmed: 33004975
J Clin Oncol. 2010 Jan 20;28(3):453-9
pubmed: 20008624
Lancet Oncol. 2015 Aug;16(8):937-48
pubmed: 26184520
Int J Cancer. 2014 Aug 1;135(3):731-41
pubmed: 24374727
Int J Oncol. 2022 Jan;60(1):
pubmed: 34913066
Can J Gastroenterol Hepatol. 2018 Jun 11;2018:7436205
pubmed: 29992127
Int J Cancer. 2011 May 1;128(9):2038-49
pubmed: 20648559
Nat Med. 2020 May;26(5):688-692
pubmed: 32405062
Nucleic Acids Res. 2022 Jan 7;50(D1):D988-D995
pubmed: 34791404
Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):2769-2784
pubmed: 29751081
Gastroenterol Rep (Oxf). 2020 Jun 23;8(3):179-191
pubmed: 32665850
Oncotarget. 2017 Mar 7;8(10):16887-16898
pubmed: 28129643
Int J Mol Sci. 2019 Nov 20;20(23):
pubmed: 31756952